Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Pemphigus (Phase 3)
CTR20212087Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) comparing Efgartigimod PH20 SC + prednisone with Placebo (rHuPH20) + prednisone (2 arms). Primary endpoint: Proportion of PV subjects achieving CRmin within 30 weeks. Started Aug 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on CTR20212087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212087.